Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.36 USD
-0.04 (-2.51%)
Updated Aug 9, 2024 04:00 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BRTX 1.36 -0.04(-2.51%)
Will BRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRTX
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
Other News for BRTX
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
BioRestorative Therapies Issues Financial Update Notice
BioRestorative Therapies? Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem? Metabolic Disease Program
BioRestorative Therapies announces notice of allowance for ThermoStem patent